Bangalore, India January 24, 2012

Biocon's nine-month revenues driven by growth in Branded Formulations, Emerging Markets and Research Services

Revenues at Rs 1,511 Crores; EBITDA at Rs 425 Crores; PAT at Rs 241 Crores

Commenting on the results, Chairman and Managing Director Kiran Mazumdar-Shaw stated, "Our performance in the first 3 quarters of FY12 has been good on the manufacturing & services fronts where profits were up nearly 29% (excluding licensing income). Licensing income, however, was sharply down from the exceptional levels recorded last fiscal which resulted in flat earnings overall. As I have frequently stated, licensing income is a timing issue and subject to periodic variability. We have seen exceptional growth in our Research Services business, an outcome of the strategic investments we have made in enhancing our integrated service offerings. Moving up the value chain is integral to our growth strategy which is reflected in the strong growth delivered by our Branded Formulations vertical. Our focus on Emerging Markets is also enabling us to realize a greater potential for our APIs and Insulins portfolios. Our R&D pipeline is advancing satisfactorily with 2 late-stage candidates and several early stage programs with enormous value creation potential through licensing. We have shaped our broad-based business into key growth verticals, which we believe will enable us to deliver sustainable, long-term value to our shareholders."

Highlights:

☑ 9 months FY12 Financials reflect a robust performance by :

- Branded Formulations vertical which grew by 40% YoY.
- Emerging Markets which now contribute ~50% of Biocon's revenues.
- Research services: 28% YoY growth in revenues, reflecting the growing traction in our integrated offering for accelerating innovation for our global customers.

☑ Announced Positive Efficacy Data on Novel Monoclonal Antibody, Itolizumab in Pivotal Phase 3 Psoriasis Study in India.

☑ Successful launch of INSUPen®, an innovative delivery device for Insulin and analogs enabling us to comprehensively expand the market through vials and cartridges.

☑ EBITDA and PAT margins at 28% and 16% respectively.

Biocon Group (consolidated; excluding Axicorp)

(Rs Crores)	3 Months Ended December 31,2011	Nine Months Ended December 31,2011
Revenues	**532**	**1,511**
EBITDA	**142**	**425**
PAT	**85**	**241**
EBITDA Margin *(%)*	**27%**	**28%**
Earnings Per Share *(Rs)*	**4.2**	**12.0**
Head Count	**6,000+ employees**	

Business Performance and Outlook (Vertical-wise)

Small Molecules & Biosimilars

A comprehensive portfolio of over 100 products spread across 70 nations has helped the Biopharma business (excluding licensing income) post 11% YoY increase in revenues in the first nine months of this fiscal. The growth in the third quarter was driven by robust performances in Immunosuppressants and the branded formulations segments.

Immunosuppressants have grown over 40% in Q3FY12 vs. Q3FY11 on the back of strong Tacrolimus and MMF sales.

Statins have remained buoyant with improved margin realization.

Biocon's Fidaxomicin commercialization partner, Optimer, has received marketing approval for DIFICLIR™ tablets in the European Union in December 2011. In its press release, Optimer has indicated plans to launch in EU by the fourth quarter of FY12 with their marketing partner Astellas Pharma. Biocon is the sole supplier of the drug substance for the global markets. Fidaxomicin is used for the treatment of adults with CDI (*Clostridium difficile* Infections) and CDAD (*Clostridium difficile*-associated diarrhea).

Dr. Arun Chandavarkar, Chief Operating Officer, Biocon Ltd, said: "We believe that our strategy of investing in technology platforms to create a differentiated API portfolio has begun to yield results as seen by the ramp up in immunosuppressant sales. Whilst we continue to expand our portfolio of APIs, we will explore select opportunities to add value through developing formulations to support our domestic branded formulations business as well as exports."

Branded Formulations

The Indian pharmaceutical market is expected to grow at a CAGR of 15% over the next 10 years and quadruple to a size of $55 billion by 2020 from a 2010 market size of $12.6 billion (IMS). The chronic therapy segment, that represents only 25% of the market, is outpacing the acute segment growth by 5 percentage points. Biocon is present in the chronic segment with over 70 brands spread across six verticals namely, Diabetology, Oncotherapeutics, Nephrology, Cardiology, Immunotherapy and Comprehensive Care. Outpacing the market, this vertical has posted a combined YoY growth of 40% for the 9MFY12.

- **Diabetology** – Biocon ranks #3 in the 4O IU insulin space, with a growth rate of 43% that outpaces the market growth of 17% (ORG IMS Nov 2011 MAT). This growth has come on the

back of our presence in the vials segment. INSUPen®, our foray into insulin delivery devices in November'11, will enable us to compete effectively in the cartridges segment thereby revving up growth. INSUPen® has garnered strong support from doctors and patients alike. It has also received accolades for its high quality and ease of use features, unique packaging of insulin Refills and a comprehensive IT- based patient-care model that also offers on-call and on-field support through 120 diabetes care advisors.

The existing product portfolio's growth as of ORG IMS MAT November 2011 was led by Basalog®, the largest brand in the Glargine vials market.

Insugen® 100 IU, a FY 10-11 launch, has made steady in-roads into the 100 IU insulin market and has garnered 8% of market share in the first year of its launch.

- **Comprehensive Care –** In the third quarter of FY12, the comprehensive care business unit delivered a strong performance driven by Albubet®, Penmer® and Biopiper®. The current portfolio was strengthened with the launch of Suprava®, Cegava® and Albubet Safe®. Within a year of the division's launch, three of its brands now feature among the top 10 brands in their respective categories.

- **Nephrology -** The third quarter of FY12 saw the Nephrology business unit deliver a strong growth driven by commendable performances in both the renal transplant and dialysis portfolios. This quarter was marked by the launch of Tacrograf® 0.25mg, the lowest strength of Tacrolimus to be launched globally for the management of post-transplant recipients on Tacrolimus.

- **Oncotherapeutics** – Abraxane® completed three years of launch in the last quarter, and is the fastest growing brand in the highly competitive taxane market. In its fifth year since launch, BIOMAb EGFR® continues to be developed via a robust clinical development program in multiple difficult-to-treat-tumors such as glioblastoma multiforme, esophageal cancer, cervical and lung cancer. BIOMAb EGFR® has gained the trust of over 250 Indian oncologists who have extended the benefit of this molecule to over 3500 Indian patients. BIOMAb EGFR® features in the 2011 Top 20 most successful New Drug Launches in India (IMS Market Intelligence).

- **Immunotherapy** – The division has grown robustly over the last quarter driven by the three flagship brands: TBIS® (Tacrolimus) PICON® (Pimecrolimus) and PSORID® (Cyclosporin). According to ORG IMS Nov 2011 MAT, TBIS® has now moved from 4th to the 3rd place value-wise over the last quarter. PICON is now ranked 2nd in volume terms as per ORG IMS November MAT 2011. The business unit also launched Calpsor® (Calcipotriol) and Calpsor C® (Calcipotriol + steroid) in the last quarter. Both these products have been well received by dermatologists.

- **Cardiology** – The Injectible portfolio has demonstrated strong growth of 55%. STATIX® (Atorvastatin) is now a visible brand in the market.

Research Services

The research services business has built on the momentum of the first half and delivered a robust 28% growth in top line for 9MFY12 vs. 9MFY11.

Syngene – This quarter saw Syngene tying up with Cellectis Bioresearch, a specialist in genome customization and a subsidiary of Cellectis for the development of novel, genetically customized cell lines by employing Syngene's biology platform.

Clinigene – In December 2011, Clinigene partnered with Pacific Biomarkers Inc. (PBI), a premier biomarker and specialty efficacy testing services provider to the American drug development industry, for addressing specialty biomarker and high-end clinical lab needs of the global pharma and biotech industry.

Commenting on this performance Peter Bains, Director, Syngene International, said, '' This has been a very encouraging quarter for Syngene. We are retaining and growing our customer base and we are seeing clear traction against our strategy to broaden our range of discovery and development capabilities to provide a more integrated service capability to support our customers changing R&D models and goals. Growth has been anchored in our small molecule discovery and development services which has been supported by encouraging acceleration in our Biologics, Discovery Biology and Custom manufacturing services".

Novel Molecules

Biocon continues to advance its novel portfolio, including the Anti-CD20 and fusion MAb programs.

Itolizumab: The phase III study for Chronic Plaque Psoriasis (TREAT-PLAQ) was completed in December 2011.Results from the **interim, 28-week data analysis** have shown **promising results,** indicating that Itolizumab has **successfully met the primary endpoint** of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo. The results also indicate that **multiple secondary endpoints after 12 and 28 weeks of treatment have also been met**. In this 28-week interim analysis**, the treatment regimens were statistically significantly better than placebo. The molecule also exhibited an excellent safety and tolerability profile** with very low rates of infection (~10%) in active treatment arms suggesting a **favorable risk benefit profile compared to currently available biologic treatments.**

IN-105: We are continuing to engage with global pharmaceutical companies for partnering the novel IN-105 oral insulin program.

Peptide Hybrid: A US IND has been filed by our partner, Amylin, for AC165198.

About Biocon

Biocon Limited (**BSE code:** 532523, **NSE Id:** BIOCON, **ISIN Id:** INE376G01013) is India's premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Established in 1978 by Dr. Kiran Mazumdar-Shaw, the Group is an integrated, innovation-driven healthcare enterprise with offerings that traverse the entire drug development value chain. Balancing its novel molecule research pipeline with a diversified product portfolio, Biocon delivers affordable solutions to partners and customers in over 70 countries across the globe. Many of these products have USFDA and EMA acceptance. Stellar products from Biocon's stable include the world's first *Pichia* based

recombinant human Insulin, INSUGEN® and glargine, BASALOG® coupled with a state of the art insulin pen device, INSUPen® and India's first indigenously produced monoclonal antibody BIOMAb-EGFR®. **www.biocon.com**

Disclaimer

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our affiliates, have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Earnings Call

The company will conduct an hour long call at 3 pm IST on January 25, 2012 where the senior management will discuss the company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The dial-in number for this call is 1800 102 1300 (India Toll Free number is accessible through all mobiles and landline services). Other toll numbers are listed in the conference call invite which is posted on the company website www.biocon.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available from January 25, 2012 – February 1, 2012 on the same dial-in numbers provided above. The transcript of the conference call will be posted on the company website.

Encl: Fact Sheet - Consolidated Income Statement and Balance Sheet (Indian GAAP)

BIOCON GROUP

F A C T S H E E T

December 2011

9M FY 2012 vs. 9M FY 2011
Q3 FY 2012 vs. Q3 FY 2011

(Rs. Crores)

BIOCON LIMITED (CONSOLIDATED) UNAUDITED
BALANCE SHEET *(Rs. Crores)*

	December-11	March -11*
SOURCES OF FUNDS		
Share Capital	100	100
Reserves & Surplus	2,197	1,933
Total Shareholder's Funds	**2,297**	**2,033**
Deferred Tax Liability	**42**	**50**
Minority Interest	**-**	**38**
Secured Loans	184	204
Unsecured Loans	192	130
Total Loans	**376**	**334**
TOTAL	**2,715**	**2,455**
APPLICATION OF FUNDS		
Fixed Assets (Net)	**1,565**	**1,356**
Intangible Assets	**250**	**234**
Investments - Liquid Funds	**575**	**400**
Investments - Others	**64**	**61**
Inventories	383	414
Sundry debtors	480	513
Cash and bank balances	388	441
Loans and advances	225	136
Total Current Assets	**1,476**	**1,503**
Less: Current liabilities	**1,215**	**1,100**
Net Current assets	**261**	**403**
TOTAL	**2,715**	**2,455**

* including Axicorp

BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT *(Rs. Crores)*

Particulars	Q3 FY 12	Q2 FY 12	Variance	Q3 FY 11	Variance
INCOME					
Biopharmaceuticals	335	351	-5%	384	-13%
Branded formulations - India	70	65	8%	47	49%
Total Biopharmaceuticals	405	416	-3%	431	-6%
Contract research	112	93	21%	79	42%
Total Sales	**517**	**509**	2%	**510**	1%
Other income	15	16	-6%	9	74%
Total Revenue	**532**	**525**	1%	**519**	3%
EXPENDITURE					
Material & Power Costs	233	237	-2%	206	13%
Staff costs	73	72	1%	57	29%
Research & Development	33	31	8%	55	-40%
Other Expenses	51	34	45%	30	72%
Manufacturing, staff & other expenses	**390**	**374**	4%	**348**	12%
PBDIT /EBITDA	**142**	**150**	-5%	**171**	-17%
Interest and finance charges	3	2	45%	6	-54%
Depreciation & Amortisation	43	43	1%	39	11%
PBT	**96**	**105**	-8%	**126**	-23%
Taxes	11	19	-40%	27	-58%
NET PROFIT (PAT) WITHOUT AXICORP	**85**	**86**	-1%	**99**	-14%
Profit from discontinued (AxiCorp) Operations, net	-	-	-	2	
NET PROFIT FOR THE PERIOD	**85**	**86**	-1%	**101**	-16%
EPS Rs.	**4.2**	**4.3**		**5.0**	
Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers					
Biopharmaceuticals Income includes:					
Licensing development fees	*29*	*36*		*58*	
Licensing Income	*-*	*1*		*19*	

BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT *(Rs. Crores)*

Particulars	9M FY 12	9M FY 11	Variance
INCOME			
Biopharmaceuticals	983	966	2%
Branded formulations - India	192	136	40%
Total Biopharmaceuticals	1,175	1,102	7%
Contract research	292	229	28%
Total Sales	**1,467**	**1,331**	10%
Other income	44	24	79%
Total Revenue	**1,511**	**1,355**	**11%**
EXPENDITURE			
Material & Power Costs	682	590	16%
Staff costs	210	160	31%
Research & Development	84	96	-13%
Other Expenses	110	83	32%
Manufacturing, staff & other expenses	**1,086**	**929**	17%
PBDIT /EBITDA	**425**	**426**	**0%**
Interest and finance charges	11	19	-45%
Depreciation & Amortisation	131	113	16%
PBT	**283**	**294**	**-4%**
Taxes	42	48	-13%
NET PROFIT (PAT) WITHOUT AXICORP	**241**	**246**	**-2%**
Profit from discontinued (AxiCorp) Operations, net	-	21	
NET PROFIT FOR THE PERIOD	**241**	**267**	**-10%**
EPS Rs.	**12.0**	**13.4**	
Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers			
Biopharmaceuticals Income includes:			
Licensing development fees	*79*	*58*	
Licensing Income	*1*	*62*	

Press Release: 2

Biocon Announces Positive Efficacy Data with its Novel Monoclonal Antibody Itolizumab in a Pivotal Psoriasis Study

Bengaluru, India /San Francisco, USA: January 9, 2012:

Biocon, Asia's premier biotechnology Company today, announced positive results from its Double Blind, Placebo Controlled, Phase 3, TREAT-PLAQ Study with **Itolizumab** in chronic plaque psoriasis. Itolizumab, the first humanized anti CD-6 monoclonal antibody, successfully met the pre-specified primary endpoint of significant improvement in PASI-75 *(Psoriasis Area and Severity Index)* score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo. It also met multiple secondary endpoints after 12 and 28 weeks of treatment.

This **52 week study conducted in India**, had a 12 week placebo controlled phase, 16 week consolidation and 24 week randomized withdrawal phase. It enrolled over 200 patients across placebo and two active treatment regimens. In this **28 week interim analysis, both treatment regimens were statistically significantly better than placebo with the fixed dose regimen** of 1.6 mg/kg every two weeks for 12 weeks followed by 1.6 mg/kg every 4 weeks for 16 weeks demonstrating response rate of 36% ($p<0.0043$) at Week 12 and 46% at Week 28. The response rates for patients with PASI> 20 at baseline was 43% and 54% at Week 12 and 28 respectively. **The molecule also exhibited an excellent safety and tolerability profile** with very low rates of infection (~10%) in active treatment arms suggesting a **favorable risk benefit profile compared to currently available biologic treatments.** Biocon plans on presenting the safety and efficacy data from the entire 52 week study at an upcoming scientific meeting.

Expressing her excitement at the outcome of the study Ms. Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon said, *"Itolizumab represents a **significant advancement** in the **treatment of psoriasis** and potentially other autoimmune diseases with **an excellent risk-benefit** profile. This could possibly become the **first novel biologic developed** and approved from India and is an **important milestone for Biocon** in its pursuit of **affordable innovation**. We look forward to taking this **molecule to the market** across multiple indications **with a global partner** to **ensure** that **affordable innovation reaches patients** worldwide in a timely manner."*

"We strongly believe in this molecule and are pleased with the results from the TREAT-PLAQ study. The low opportunistic infection rate despite the study being conducted in India validates the preclinical findings and along with ***novel mechanism of action opens new treatment paradigms*** *for treatment of psoriasis and other autoimmune diseases. We are looking forward to accelerating clinical development in other autoimmune conditions like MS (Multiple Sclerosis) and RA (Rheumatoid Arthritis)"* said **Abhijit Barve, M.D., Ph.D., President R&D, Biocon.** ***"****We would like to sincerely thank all the patients and their families, investigators and colleagues at Biocon, Clinigene and other partners for their participation in this complex study*"

About Itolizumab

Itolizumab is a 'first-in-class' investigational humanized IgG1 monoclonal antibody that selectively targets CD6 cells. CD 6 is a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation. In addition to TREAT-PLAQ study, two positive Phase 2a dose finding studies have been conducted one each in RA and psoriasis. A total of about 300 patients have been treated with Itolizumab, of these, about 100 patients have received the drug for 52 weeks with encouraging safety and tolerability profile.

About Biocon Limited

Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest biotechnology Company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon's value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. Biocon's robust product offering includes the world's first Pichia-based recombinant Human Insulin, INSUGEN(R) and India's first indigenously produced monoclonal antibody BIOMAb-EGFR(TM) www.biocon.com

Media Contact:	
Seema Ahuja **Head-Corporate Communication** Biocon Limited T: +91-80-2808-2222, M:+919972317792 Email:seema.ahuja@biocon.com	**Varija Belliappa** **Assistant Manager-Corp Commn** Biocon Limited Tel: +91 80 2808 2223 M:+9880133507 Email: varija.belliappa@biocon.com

Clinigene International Enters into Collaborative Clinical Research Services Agreement with Pacific Biomarkers

Press Release: 3

Bangalore, India – December 21, 2011: Clinigene International Limited, a subsidiary of Biocon, India's largest Biotech Company, and Pacific Biomarkers Inc. (PBI), a Seattle, WA-based limited liability company announce a collaborative agreement to address the specialty biomarker and high-end clinical trial laboratory needs of the global pharmaceutical and biotechnology industry.

Clinigene, is an India-based Clinical Research Organization (CRO) that offers end-to-end clinical and laboratory services for accelerating clinical research, and Pacific Biomarkers Inc. (PBI), is a Seattle, WA-based company that provides premier biomarker and specialty efficacy testing services to the drug development industry.

"*PBI is a recognized global leader in providing specialty biomarkers and clinical diagnostic assay services to discovery- and development-based life science enterprises. We are delighted that PBI has selected Clinigene as its partner in India and we look forward to supporting PBI in extending and expanding its specialist service offerings*,'' said Peter Bains, Director of Research Services business.

"*This partnership with Clinigene provides us access to India, an emerging hub for drug development and contract research. Further, Clinigene's state-of-the-art facilities and highly qualified staff help us offer to all of our clients an economic option to conduct their biomarker and specialty clinical lab tests. We are also excited about Clinigene' s unique capabilities in cell-based assays and immunoanalytical testing services, which are of great interest to the global pharmaceutical and biotechnology community*," said Ronald Helm, CEO of Pacific Biomarkers.

About Clinigene International Limited

Established in 2000, Clinigene *(www.clinigeneintl.com)* a fully owned subsidiary of Biocon Limited, is a full-service Contract Research Organization (CRO) providing early-stage as well as late-phase clinical solutions, and central laboratory, immunoanalytical and data management services. Clinigene operates a CAP-accredited Central Lab and GLP-compliant Bioanalytical Laboratory for small and large molecules, and a 104-bed clinical pharmaceutical unit in Bangalore, India. Clinigene' s early-phase clinic and laboratories have been inspected by EMEA and the US FDA.

About Biocon Limited

Biocon is Asia's premier Biotechnology Company and India's largest by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. *(www.biocon.com)*

About Pacific Biomarkers (PBI)

Established in 1989, PBI (www.pacbio.com) provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotechnology, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, mass spectrometry, and multiplex testing.

Media Contact:

Seema Ahuja
Head- Corporate Communications
Biocon Limited
Tel: +91 80 2808 2222
Fax: +9180 2852 3423
Email: seema.ahuja@biocon.com

Varija Belliappa
Asst Manager-Corporate Communications
Biocon Limited
Tel: +91 80 2808 2223
Fax: +9180 2852 3423
Email: varija.belliappa@biocon.com